Press "esc" to clear
Go to Advanced Search

Showing results

110 of 403

Article ID: 703725

ATS Opposes FDA Decision to Approve Over-the-Counter Epinephrine for the Treatment of Asthma

American Thoracic Society (ATS)

The American Thoracic Society is gravely concerned and disappointed in the FDA’s decision to approve over the counter epinephrine (Primatene Mist HFA) for consumer use to treat asthma. The ATS is a medical professional society dedicated to the prevention, detection, treatment and research of pulmonary disease, critical care illness and sleep disordered breathing. Our members are experts in the diagnosis and management of asthma and have published several clinical practice guidelines for the treatment of asthma. It is with our extensive clinical expertise in the treatment of asthma and our concern for the patients that we oppose the FDA’s decision.

Released:
9-Nov-2018 12:05 PM EST

Article ID: 703638

ACAAI Warns Against Stopping Use of Your Prescription Asthma Medication for Primatene Mist

American College of Allergy, Asthma and Immunology (ACAAI)

The American College of Allergy, Asthma and Immunology warns those with asthma not to stop using their prescription medications in favor of Primatene Mist.

Released:
8-Nov-2018 12:05 PM EST
Embargo will expire:
16-Nov-2018 12:00 AM EST
Released to reporters:
8-Nov-2018 8:00 AM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 16-Nov-2018 12:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
16-Nov-2018 12:00 AM EST
Released to reporters:
8-Nov-2018 8:00 AM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 16-Nov-2018 12:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
19-Nov-2018 9:00 AM EST
Released to reporters:
8-Nov-2018 8:00 AM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 19-Nov-2018 9:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
16-Nov-2018 12:00 AM EST
Released to reporters:
8-Nov-2018 8:00 AM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 16-Nov-2018 12:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
16-Nov-2018 12:00 AM EST
Released to reporters:
8-Nov-2018 8:00 AM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 16-Nov-2018 12:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
16-Nov-2018 12:00 AM EST
Released to reporters:
8-Nov-2018 8:00 AM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 16-Nov-2018 12:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
16-Nov-2018 12:00 AM EST
Released to reporters:
8-Nov-2018 8:00 AM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 16-Nov-2018 12:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
16-Nov-2018 12:00 AM EST
Released to reporters:
8-Nov-2018 8:00 AM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 16-Nov-2018 12:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


Showing results

110 of 403

Chat now!